Laura Moschcovich, PhD

 General Manager

Dr. Laura Moschcovich joined OPKO Biologics (formerly Prolor Biotech) in 2007 as the Head of Downstream Development, leading the development of the purification process of MOD-4023 (CTP-growth hormone). In 2012 she became Project Manager responsible for overseeing three different projects in collaboration with different CMOs, taking the responsibility of the technology transfer of the processes developed at OPKO Biologics from development to production. Previously she led the CMC activities as Vice President, CMC Operationsof the Company and worked at Target-In Ltd., an Israeli startup company in a partnership with the Hebrew University of Jerusalem, as Head of Downstream Development where she was responsible for the development of the purification process of an innovative product. Dr. Moschcovich completed a post-doctoral fellowship and received her PhD in Biochemistry from Tel Aviv University.

Yifat Philip, LLB, MBA

Vice President, Legal Affairs and Human Resources

Yifat Philip joined OPKO Biologics in 2013 and leads the company’s legal department. In addition, she is a member of the management team and responsible for the HR field in the company. Yifat has been practicing law for more than 15 years, with previous experience in leading law firms on international biotech transactions, as well as in the Israel Securities Authorities, the Department of Economics and Fiscal Law of the State Attorney, Israel. Yifat is a member of the Israel Bar Association. She holds an LLB cum laude and Bachelor’s Degree in Economics from Haifa University; Master cum laude in Law and Economics from Erasmus University in the Netherlands in collaboration with Berkeley University, USA; and an MBA from the Technion-Israel Institute of Technology, Israel. Yifat also serves as a member of the board of directors of the Israeli Association of Corporate Counsels.

Ahuva Bar-Ilan, PhD

VP Preclinical and Clinical Pharmacology

Ahuva Bar-Ilan joined OPKO Biologics (formely ModigeneTech and Prolor Biotech) in December 2006 as a senior scientist in the R&D department. Since 2012, she was an Associate Director at Prolor Biotech and was responsible for the development of immunogenicity and bio-analytical methods. Currently, she is a Director at OPKO’s pre-clinical department and is responsible for methods validation, toxicological and pharmacological activities. Prior to joining Modigentech, she was a senior scientist at NatSpears. Dr. Bar-Ilan completed her PhD in the Biochemistry and Microbiology department at Ben-Gurion University of the Negev, Israel.

Sagit Pinto-Finkel, CPA MBA

VP Finance

Sagit Pinto-Finkel joined OPKO Biologics in 2014. In 2015, she became the Director of Clinical Finance, and is responsible for all financial aspects of the clinical department.
Sagit has over 20 years of progressive experience in finance and business positions in pharma, high-tech and communications companies including multinational, private, and publically traded corporations.
Sagit is a CPA, holds a Bachelor’s Degree in Economics and Accounting from The Hebrew University, Jerusalem and an MBA, with a major in Finance (Cum Laude) from Tel Aviv University.

Guy Ben-Bashat, MA

Senior Director of Clinical Affairs

Guy joined Opko Biologics in 2015 and is extensively involved with the company products development programs. Guy is responsible for co-leading and planning the infrastructure supporting and executing the global clinical research activities of Opko Biologics, conducted in more than 40 countries worldwide and hundreds of investigational sites. Prior to joining Opko Biologics Guy was responsible for clinical innovative projects in Dexcel Pharma Ltd. the second largest pharmaceutical company in Israel. Guy has over 15 years of clinical research and clinical development experience in the pharmaceutical and medical device industries. Guy is a licensed Psychologist and a Neuropsychologist by training and holds a Master Degree (Cum Laude) in Neuropsychology from Ben-Gurion University.

Miri Gerzon-Zakar 

Director of CMC

Miri joined OBL in 2011 as a Research associate in downstream development department. In the following years, Miri held a variety of R&D positions including Associate Director of Downstream development and Senior Associate Director of Upstream Development. Prior joining OBL, Miri served as a Research assistant in an academic laboratory and Teaching assistant at the Department of Life Sciences at the Ben-Gurion University. Miri completed her M.Sc. and B.Sc. Magna (cum laude) in Life Sciences at Ben Gurion University.

Dana Avraham

Director Of QA

Dana had joined OPKO Biologics (formerly Prolor-Biotech) in the end of 2015 as Clinical QA in the Clinical department. She had functioned as the Operational team manager and Records Management team manager from 2017 to 2019, leading the Operational team of MOD-4023 (growth hormone CTP) in phase II and phase III global clinical trials and the Records Management team responsible for eTMF management of OPKO Biologics clinical trials. Since the end of 2019 Dana is leading the QA activities. Previously she worked as Quality Engineer in Omrix biopharmaceuticals, a Johnson & Johnson company. Dana holds a B.Sc. in Biotechnology Engineering from the Ben Gurion University of the Negev.